专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012004005A1 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION 审中-公开
标题翻译：包含羟基烷基淀粉和细胞毒素的方法及其制备方法
公开(公告)号：WO2012004005A1
公开(公告)日：2012-01-12
申请号：PCT/EP2011/003458
申请日：2011-07-11
申请人： FRESENIUS KABI DEUTSCHLAND GMBH , KNOLLER, Helmut , HECKMANN, Dominik , HACKET, Frank , ZANDER, Norbert , NOCKEN, Frank
发明人： KNOLLER, Helmut , HECKMANN, Dominik , HACKET, Frank , ZANDER, Norbert , NOCKEN, Frank
IPC分类号： A61K47/48 , A61P35/00
CPC分类号： A61K47/4823 , A61K47/36 , A61K47/61 , C08B31/10
摘要： The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS'(-L-M) n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS' is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.
摘要翻译：本发明涉及羟烷基淀粉缀合物及其制备方法，所述羟烷基淀粉缀合物包含羟烷基淀粉衍生物和细胞毒性剂，所述细胞毒性剂包含至少一个仲羟基，其中所述羟烷基淀粉通过所述仲羟基对细胞毒性剂。根据本发明的缀合物具有根据下式HAS'（ - LM）n的结构，其中M是细胞毒性剂的残基，L是连接部分，HAS'是羟烷基淀粉衍生物的残基，以及 n大于或等于1，并且其中羟烷基淀粉衍生物具有高于肾阈值的平均分子量（MW）。

2. 发明申请

WO2012004008A1 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION 审中-公开
标题翻译：包含羟基烷基淀粉和细胞毒素的方法及其制备方法
公开(公告)号：WO2012004008A1
公开(公告)日：2012-01-12
申请号：PCT/EP2011/003461
申请日：2011-07-11
申请人： FRESENIUS KABI DEUTSCHLAND GMBH , KNOLLER, Helmut , HECKMANN, Dominik , HACKET, Frank , ZANDER, Norbert , NOCKEN, Frank
发明人： KNOLLER, Helmut , HECKMANN, Dominik , HACKET, Frank , ZANDER, Norbert , NOCKEN, Frank
IPC分类号： C08B31/12 , C08L3/08 , A61K47/48
CPC分类号： C08B31/10 , A61K47/61 , C08B31/12 , C08L3/08
摘要： The present invention relates to hydroxyalkyl starch conjugates, a method for preparing the same, the hydroxyalkyi starch conjugate comprising a hydroxyalkyi starch derivative and a cytotoxic agent and the cytotoxic agent comprising at least one tertiary hydroxyl group, wherein the hydroxyalkyi starch is linked via said tertiary hydroxyl group to the cytotoxic agent. The conjugates according to the present invention have a structure according to the following formula HAS'(-L-M) n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS' is the residue of the hydroxyalkyi starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyi starch derivative has a mean molecular weight (MW) above the renal threshold.
摘要翻译：本发明涉及羟烷基淀粉共轭物，其制备方法，包含羟基烷基淀粉衍生物和细胞毒性剂的羟基烷基淀粉缀合物和包含至少一个叔羟基的细胞毒性剂，其中所述羟基烷基淀粉通过所述第三级羟基对细胞毒性剂。根据本发明的缀合物具有根据下式HAS'（ - LM）n的结构，其中M是细胞毒性剂的残基，L是连接部分，HAS'是羟基烷基淀粉衍生物的残基，以及 n大于或等于1，并且其中羟烷基淀粉衍生物的平均分子量（MW）高于肾阈值。

3. 发明申请

WO2012004006A1 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION 审中-公开
标题翻译：包含羟基烷基淀粉和细胞毒药物的共轭物及其制备方法
公开(公告)号：WO2012004006A1
公开(公告)日：2012-01-12
申请号：PCT/EP2011/003459
申请日：2011-07-11
申请人： FRESENIUS KABI DEUTSCHLAND GMBH , KNOLLER, Helmut , HECKMANN, Dominik , HACKET, Frank , ZANDER, Norbert , NOCKEN, Frank
发明人： KNOLLER, Helmut , HECKMANN, Dominik , HACKET, Frank , ZANDER, Norbert , NOCKEN, Frank
IPC分类号： A61K47/48 , A61P35/00
CPC分类号： A61K47/4823 , A61K47/36 , A61K47/61 , C08B31/10
摘要： The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS'(-L-M) n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS' is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.
摘要翻译：本发明涉及羟烷基淀粉缀合物及其制备方法，所述羟烷基淀粉缀合物包含羟烷基淀粉衍生物和细胞毒性剂，所述细胞毒剂包含至少一个仲羟基，其中羟烷基淀粉通过所述仲羟基与细胞毒性剂连接。根据本发明的缀合物具有根据下式的结构HAS'（ - LM）n其中M是细胞毒剂的残基，L是连接部分，HAS'是残基的羟烷基淀粉衍生物，并且n大于或等于1，并且其中羟烷基淀粉衍生物具有高于肾阈值的平均分子量（MW）。

4. 发明申请

WO2016120490A1 USE OF A MIXTURE OF MODIFIED GLUCOSE POLYMERS FOR REDUCING TUMOR METASTASIS 审中-公开
标题翻译：使用改性葡萄糖聚合物混合物减少肿瘤分化
公开(公告)号：WO2016120490A1
公开(公告)日：2016-08-04
申请号：PCT/EP2016/052076
申请日：2016-02-01
申请人： FRESENIUS KABI DEUTSCHLAND GMBH
发明人： SUNDERMANN, Bernd , WALZ, Lars , BAASNER, SIlke , NOCKEN, Frank , MEYER, Christoph
IPC分类号： A61K31/01 , A61P35/00
CPC分类号： A61K31/721 , A61K9/08 , A61K31/01 , A61K31/718
摘要： The present invention relates to a solution, in particular a pharmaceutically acceptable solution, comprising icodextrin and hydroxyalkyl starch (HAS), wherein the icodextrin is present at a concentration of from 1 to 7.5 % (w/v) and wherein said HAS is present at a concentration of from 1 to 15 % (w/v). The present invention further relates to the aforesaid pharmaceutically acceptable solution for use as a medicament and for use in (e.g., in methods of) preventing metastasis formation and/or relapse by administration to a body cavity of a subject afflicted with cancer. The present invention further relates to a kit comprising icodextrin and HAS in pre- weighed amounts and a pharmaceutically acceptable means of dissolving the same, to a device comprising a pharmaceutically acceptable solution of the present invention and means for administering the same, as well as to a pharmaceutically acceptable solution comprising icodextrin and hydroxyalkyl starch at a total concentration in the range of from 1 to 20 % (w/v), wherein the weight ratio of the icodextrin relative to the hydroxyalkyl starch is in the range of from 0.05:1 to 5:1, for use in preventing metastasis formation and/or relapse by administration to a body cavity of a subject afflicted with cancer.
摘要翻译：本发明涉及包含icodextrin和羟烷基淀粉（HAS）的溶液，特别是药学上可接受的溶液，其中所述icodextrin以1至7.5％（w / v）的浓度存在，并且其中所述HAS存在于浓度为1至15％（w / v）。本发明还涉及用作药物并用于（例如，通过施用于患有癌症的受试者的体腔）的转移形成和/或复发的方法中的上述药学上可接受的溶液。本发明还涉及一种试剂盒，其包含预先称量的艾司糊精和HAS以及将其溶解的药学上可接受的方法，包括本发明的药学上可接受的溶液的装置和用于施用本发明的药物的方法，以及一种药学上可接受的溶液，其包含浓度为1至20％（w / v）范围内的浓度为1至20％（重量/体积）的艾司糊精和羟烷基淀粉，其中，所述羟丙基纤维素与所述羟烷基淀粉的重量比在0.05:1至 5：1，用于通过施用于患有癌症的受试者的体腔来预防转移形成和/或复发。

5. 发明申请

WO2015014730A1 POLYSACCHARIDE FOR USE IN PREVENTING METASTASIS FORMATION AND/OR RELAPSE 审中-公开
标题翻译：多糖用于预防转移形成和/或再生
公开(公告)号：WO2015014730A1
公开(公告)日：2015-02-05
申请号：PCT/EP2014/065990
申请日：2014-07-25
申请人： FRESENIUS KABI DEUTSCHLAND GMBH
发明人： SUNDERMANN, Bernd , WALZ, Lars , BAASNER, Silke , NOCKEN, Frank , MEYER, Christoph
IPC分类号： A61K31/716 , A61K31/718 , A61K31/721 , A61P35/04 , A61K9/08
CPC分类号： A61K31/715 , A61K9/0019 , A61K9/08 , A61K31/716 , A61K31/718 , A61K31/721 , A61K47/02 , A61K47/36
摘要： The present invention relates to a polysaccharide comprising, optionally substituted, monosaccharide units linked via alpha-glycosidic bonds for use in preventing metastasis formation and/or relapse by administration to a body cavity of a subject afflicted with cancer. The present invention further relates to a method for preventing metastasis formation in a subject afflicted with cancer, comprising administering said composition to a body cavity of said subject, and thereby preventing metastasis formation in said subject. The present invention also relates to a composition and to a kit comprising a polysaccharide and a pharmaceutically acceptable means of solubilizing the same and to a device comprising a polysaccharide and means for administering the same.
摘要翻译：本发明涉及包含通过α-糖苷键连接的任选取代的单糖单元的多糖，其用于通过给予罹患癌症的受试者的体腔以预防转移形成和/或复发。本发明进一步涉及用于预防患有癌症的受试者中的转移形成的方法，所述方法包括将所述组合物施用至所述受试者的体腔，从而防止所述受试者转移形成。本发明还涉及一种组合物和一种包含多糖及其药学上可接受的溶解手段的试剂盒和一种包含多糖的装置和用于施用多糖的装置。

6. 发明申请

WO2008028680A3 VERFAHREN ZUR UNTERSTÜTZUNG VON IMMUNTHERAPIEN 审中-公开
公开(公告)号：WO2008028680A3
公开(公告)日：2008-03-13
申请号：PCT/EP2007/007840
申请日：2007-09-07
申请人： FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH , FRESENIUS BIOTECH GMBH , HEPPER, Martin , LEINENBACH, Hans, Peter , NOCKEN, Frank
发明人： HEPPER, Martin , LEINENBACH, Hans, Peter , NOCKEN, Frank
IPC分类号： A61M1/36
摘要： Die vorliegende Erfindung betrifft ein Ex-vivo Verfahren zur Erhöhung der Wirksamkeit von Antikörpern und Fcγ- Rezeptor bindenden Wirkstoffen, umfassend die Schritte des: a) Bereitstellens einer Blutprobe eines Patienten; b) Unterwerfens der Blutprobe einer Immunapherese; c) Verabreichens eines therapeutisch wirksamen Antikörpers oder eines Fcγ-Rezeptor-bindenden Wirkstoffs an den Patienten.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式